WHAT ARE CLINICAL TRIALS AND WHY ARE THEY IMPORTANT?
Federally Supported Clinical Trials
Clinical Trials Open To Accrual
Breast
Protocol
B-37 (anticipate closure to accrual in January 2010)
Protocol
B-39
Protocol
B-40
Protocol B-43
Colorectal
Protocol C-11 (anticipate activation before mid-2010)
Protocol
R-04
Back To Top
Industry Supported Clinical Trials
In 2002, realizing the need to have experience with new pharmaceutical agents earlier
in their development cycle, NSABP established the Foundation Research Program (FRP),
in which Phase II studies totally supported by industry are carried out. This was
done primarily to allow the NSABP to test agents in the Phase II setting and be
able to move them directly into our Phase III program. Since completing the FRP
pilot program, we have published the results of the first several Phase II studies.
In 2007, NSABP made the commitment to broaden the industry supported trials conducted
by NSABP to include Phase III studies. The Division of Industry Trials, with employees
dedicated solely to industry supported studies, includes these Phase III studies and the Phase II studies
conducted under the FRP.
Phase III Industry Trials Open To
Accrual
Breast
Cancer
Protocol
B-41
Protocol B-44-I
Protocol B-46-I
Colon Cancer
VELOUR Trial
Phase II FRP Industry Trials Open To
Accrual
Breast
Cancer
Protocol FB-6
Colon Cancer
Protocol FC-4
Protocol FC-6 (anticipate activation early in 2010)
Back To Top
Division of Pathology & NSABP Biospecimen Bank
NSABP Biospecimen Bank
For more than 35 years, as part of all NSABP Phase III studies, biospecimens have
been collected from patients participating in those NSABP clinical trials. The result is
a repository housing biospecimens from more than 90,000 patients for
whom clinical follow-up data is available. This data links the biospecimen
with the results of the treatment, making the NSABP Biospecimen Bank a
unique research resource. The Biospecimen Bank, with its archival tumor specimens
and extensive NSABP clinical data base, has been deemed a “national treasure” by
the NCI.
The NSABP researchers based in Pittsburgh have utilized the specimens in conjunction
with industry and academic investigators to evaluate molecular markers in a series of studies that has been
aimed at defining prognosis and response to chemotherapy and interesting agents in patients who have participated
in our studies. Our first collaborative effort resulted in a laboratory test, called
Oncotype DX, which has been commercially available throughout the world. We see the
utilization of this valuable biospecimen bank resource as an opportunity for future advances
in both breast and colon cancer.
The NSABP is the steward of the biospecimen repositories and sees as part of its responsibility
the sharing of biospecimens with others both in academia and in industry,
along with providing access to the related clinical data. To that end, we have established
a formal procedure for requesting biospecimen resources from the banks. In addition to the NSABP’s
own research activities, other investigators in the broad scientific community
have met the established qualifications and have received approval for the use of
NSABP biospecimens. We are the first national clinical trials group to have established
such an open access program.
NSABP Division of Pathology
Contacts and Information
NSABP Pathology Laboratory Grand Opening (October 2006)
Back To Top